A Clinical Trial to Evaluate the Blood Pressure Control of Telmisartan or Losartan in Essential Hypertensive Patients With Metabolic Syndrome

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 116 participants.

Also called NCT05843162

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 116 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT05843162
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT05843162. Randomized; no masking; primary purpose treatment. Start 2023-06-01 (anticipated); primary completion 2023-12-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Clinical Trial to Evaluate the Blood Pressure Control of Telmisartan or Losartan in Essential Hypertensive Patients With Metabolic Syndrome
Acronym
PRISTINE
Condition
Essential Hypertension
Intervention (Drug)
Telmisartan
Intervention (Drug)
Losartan
Lead sponsor
Chong Kun Dang Pharmaceutical (class: industry)

Record details

Record id
cardio:ct-nct05843162
Content hash
34c9cc35a6049ce0b422b3b46b6b6945be74d3057544f77ed9c7fff841c0855b